98%
921
2 minutes
20
Background: Rapidly evolving evidence, from preclinical and clinical studies, indicates a possible connection between inflammatory bowel disease and periodontitis. This study aimed to summarize the evidence from preclinical in vivo studies regarding the possible link between periodontitis and colitis.
Methods: A systematic literature search was performed and resulting studies were screened against predefined eligibility criteria; data from included studies were extracted, and meta-analyses were performed whenever possible.
Results: Thirty-four publications using mice or rats were included; 26 experiments evaluated the effect of inoculation with oral bacteria on experimental colitis, 3 the effect of experimental periodontitis on experimental colitis, and 7 the effect of experimental colitis on periodontal status; 45% (9), 78% (14), 57% (12), and 89% (16) of the studies found a significantly higher body weight loss, shorter colon length, higher disease activity index (DAI), and higher intestinal histopathological assessment scores (IHA), respectively, in animals exposed to inoculation with oral bacteria and experimental colitis compared with animals with only colitis. Meta-analyses confirmed that inoculation with oral bacteria significantly aggravated colitis, that is, significant negative overall effect on body weight, colon length, DAI, and IHA. Among the tested bacteria, Fusobacterium nucleatum had the strongest effect followed by Porphyromonas gingivalis. The results of the remaining interactions and comparisons are inconclusive due to a limited number of studies and differences in study design.
Conclusions: Inoculation with the periodontitis-associated bacteria F. nucleatum and probably also P. gingivalis exacerbates experimental colitis in mice. It is yet unclear whether colitis can affect periodontal health and/or disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ibd/izaf087 | DOI Listing |
J Cell Mol Med
September 2025
Department of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
This study aims to assess whether endometriosis causally increases the risk of IBD through Mendelian randomisation (MR) analysis and to elucidate potential mechanisms using in vitro experiments. A two-sample Mendelian randomisation (MR) analysis was conducted using genome-wide association study datasets for endometriosis and IBD, including ulcerative colitis and Crohn's disease. Causal inference was assessed using inverse variance weighting, MR-Egger, and weighted median methods, with MR-PRESSO used to detect horizontal pleiotropy.
View Article and Find Full Text PDFUrol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.
Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.
Int J Biol Macromol
September 2025
School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, PR China. Electronic address:
Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by disruption of intestinal barrier function and complex inflammatory manifestations locally and systemically. Although anti-tumor necrosis factor-α (TNF-α) agents such as Infliximab (IFX) are effective in treating IBD, their intestinal tissue concentration has been regarded as determinant of therapeutic efficacy while was restrained by the large molecular weight. Considering the enhanced expression of human neonatal Fc receptor (hFcRn) in UC tissues, we attempted to deliver the therapeutic entity of IFX into UC tissues by developing a novel dual-acting IFX Fab-F8 (IFX-F8) fusion protein for UC treatment.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Clinical Pharmacy Department, School of Pharmacy, Newgiza University, Giza, Egypt. Electronic address:
Ulcerative colitis (UC) is a persistent inflammatory condition marked by the destruction of the intestinal mucosal barrier, infiltration of inflammatory cells, and ulceration. M1/M2 macrophage polarization plays an imperative function in the regulation of inflammation through the nuclear factor-kappa B (NFκB) signaling pathway and modulating microRNA-155 (miR-155). Recent studies have highlighted the anti-ulcerogenic and colo-protective properties of sodium-glucose co-transporter-2 (SGLT2) inhibitors.
View Article and Find Full Text PDFEur J Pharmacol
September 2025
Zydus Research Centre, Zydus Lifesciences Limited, Sharkhej-Bavla NH No. 8A, Village Moraiya, Changodar, Ahmedabad-382 213, Gujarat, India.
NLR (Nod-like receptor) family pyrin domain containing protein 3 (NLRP3) inflammasome activation is key component of innate immune response and is implicated in many autoimmune conditions. Usnoflast is a novel, selective NLRP3-inflammasome inhibitor and is currently in Phase II for various indications including Ulcerative colitis. Here, we report the effect of usnoflast in several experimental models of intestinal inflammation, some of them for the first time for any NLRP3 inhibitor, which involves both innate and adaptive immune mechanisms.
View Article and Find Full Text PDF